Better Classification of Respiratory Amyloidosis

NCT ID: NCT05862961

Last Updated: 2023-05-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-15

Study Completion Date

2026-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The B-AR project is based on a retrospective analysis of amyloidosis typing and the identification of their amylogenic protein.This work should be able to unite many clinicians, including pulmonologists and pathologists around a rare disease that still suffers from insufficient data.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The B-AR study will highlight the interest of proteomic analysis of amyloidosis compared to their identification by immunostaining. The objective is to reduce diagnostic wandering and to improve patient management. The typing of respiratory amyloidosis will allow a better characterization of the disease and thus, to propose a dedicated therapeutic management.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient \> to 18 years with amyloidosis on a histological sample of the tracheobronchial or pulmonary tree.

Exclusion Criteria

* Subject receiving state medical aid
* Subject deprived of freedom, or under a legal protective measure (example: patients under guardianship or curators)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yurdagül UZUNHAN, Pr,MD, PhD

Role: STUDY_DIRECTOR

APHP Hôpital Avicenne

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yurdagül UZUNHAN, Pr,MD, PhD

Role: CONTACT

01 48 95 52 80

Magali COLOMBAT, MD PhD

Role: CONTACT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP220270

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PL_GNT01_ISR_Grant 53234273
NCT06714019 ENROLLING_BY_INVITATION
Essen Amyloidosis Registry
NCT06887283 RECRUITING
Brasilia Heart Study
NCT02062554 UNKNOWN